• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neurofibromatosis Clinical Trials-REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead.

作者信息

Gross Andrea M, Plotkin Scott R, Widemann Brigitte C

机构信息

From the Pediatric Oncology Branch (A.M.G., B.C.W.), Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston.

出版信息

Neurology. 2021 Aug 16;97(7 Supplement 1):S1-S3. doi: 10.1212/WNL.0000000000012429.

DOI:10.1212/WNL.0000000000012429
PMID:34230201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11418092/
Abstract
摘要

相似文献

1
Neurofibromatosis Clinical Trials-REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead.神经纤维瘤病临床试验 - REiNS合作组织2020年建议：回顾与展望
Neurology. 2021 Aug 16;97(7 Supplement 1):S1-S3. doi: 10.1212/WNL.0000000000012429.
2
Achieving consensus for clinical trials: the REiNS International Collaboration.达成临床试验共识：REiNS 国际合作。
Neurology. 2013 Nov 19;81(21 Suppl 1):S1-5. doi: 10.1212/01.wnl.0000435743.49414.b6.
3
Conclusions and future directions for the REiNS International Collaboration.REiNS 国际合作的结论和未来方向。
Neurology. 2013 Nov 19;81(21 Suppl 1):S41-4. doi: 10.1212/01.wnl.0000435748.79908.c5.
4
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.神经纤维瘤病和施万细胞瘤病临床试验设计进展：神经纤维瘤病和施万细胞瘤病反应评估（REiNS）国际协作组的共识建议
Clin Trials. 2024 Feb;21(1):3-5. doi: 10.1177/17407745231201345. Epub 2023 Sep 29.
5
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.通过患者参与增强神经纤维瘤病临床试验的结果测量：REiNS 的经验教训。
Neurology. 2021 Aug 17;97(7 Suppl 1):S4-S14. doi: 10.1212/WNL.0000000000012430. Epub 2021 Jul 6.
6
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.神经纤维瘤病临床试验中患者报告的疼痛和身体功能结果。
Neurology. 2016 Aug 16;87(7 Suppl 1):S4-S12. doi: 10.1212/WNL.0000000000002927.
7
Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.《神经纤维瘤病 2 型患者的听力报告：临床试验建议》。
Neurology. 2021 Aug 17;97(7 Suppl 1):S64-S72. doi: 10.1212/WNL.0000000000012424. Epub 2021 Jul 6.
8
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.神经纤维瘤病和雪旺氏细胞瘤病临床试验中的患者报告结局。
Neurology. 2013 Nov 19;81(21 Suppl 1):S6-14. doi: 10.1212/01.wnl.0000435747.02780.bf.
9
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.当前用于神经纤维瘤病临床试验中评估生活质量领域的患者报告结局测量的推荐意见。
Neurology. 2021 Aug 17;97(7 Suppl 1):S50-S63. doi: 10.1212/WNL.0000000000012421. Epub 2021 Jul 6.
10
Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.神经纤维瘤病临床试验中的神经认知结果：注意力领域的建议
Neurology. 2016 Aug 16;87(7 Suppl 1):S21-30. doi: 10.1212/WNL.0000000000002928.

引用本文的文献

1
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.神经纤维瘤病和施万细胞瘤病临床试验设计进展：神经纤维瘤病和施万细胞瘤病反应评估（REiNS）国际协作组的共识建议
Clin Trials. 2024 Feb;21(1):3-5. doi: 10.1177/17407745231201345. Epub 2023 Sep 29.
2
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.通过患者参与增强神经纤维瘤病临床试验的结果测量：REiNS 的经验教训。
Neurology. 2021 Aug 17;97(7 Suppl 1):S4-S14. doi: 10.1212/WNL.0000000000012430. Epub 2021 Jul 6.
3
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.精准医学时代的神经纤维瘤病：MEK 抑制剂的发展和 Selumetinib 的最新成功
Curr Oncol Rep. 2021 Mar 15;23(4):45. doi: 10.1007/s11912-021-01032-y.
4
An Update on Neurofibromatosis Type 1-Associated Gliomas.1型神经纤维瘤病相关胶质瘤的最新进展
Cancers (Basel). 2020 Jan 1;12(1):114. doi: 10.3390/cancers12010114.

本文引用的文献

1
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.通过患者参与增强神经纤维瘤病临床试验的结果测量：REiNS 的经验教训。
Neurology. 2021 Aug 17;97(7 Suppl 1):S4-S14. doi: 10.1212/WNL.0000000000012430. Epub 2021 Jul 6.
2
Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.神经纤维瘤病的基因型-表型相关性及其潜在的临床应用。
Neurology. 2021 Aug 17;97(7 Suppl 1):S91-S98. doi: 10.1212/WNL.0000000000012436. Epub 2021 Jul 6.
3
Recommendations for Measurement of Attention Outcomes in Preschoolers With Neurofibromatosis.建议在患有神经纤维瘤病的学龄前儿童中测量注意力结果。
Neurology. 2021 Aug 17;97(7 Suppl 1):S81-S90. doi: 10.1212/WNL.0000000000012423. Epub 2021 Jul 6.
4
Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1.推荐用于神经纤维瘤病 1 型临床试验的社交技能终点。
Neurology. 2021 Aug 17;97(7 Suppl 1):S73-S80. doi: 10.1212/WNL.0000000000012422. Epub 2021 Jul 6.
5
Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.测量神经纤维瘤病 1 型皮肤神经纤维瘤对生活质量的影响。
Neurology. 2021 Aug 17;97(7 Suppl 1):S25-S31. doi: 10.1212/WNL.0000000000012427. Epub 2021 Jul 6.
6
Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.《神经纤维瘤病 2 型患者的听力报告：临床试验建议》。
Neurology. 2021 Aug 17;97(7 Suppl 1):S64-S72. doi: 10.1212/WNL.0000000000012424. Epub 2021 Jul 6.
7
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.神经纤维瘤病 1 型成年患者的观点：对临床试验的启示。
Neurology. 2021 Aug 17;97(7 Suppl 1):S15-S24. doi: 10.1212/WNL.0000000000012425. Epub 2021 Jul 6.
8
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.1 型神经纤维瘤病丛状神经纤维瘤的影像学评估：基于调查的评估。
Neurology. 2021 Aug 17;97(7 Suppl 1):S111-S119. doi: 10.1212/WNL.0000000000012437. Epub 2021 Jul 6.
9
Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.纳入皮肤神经纤维瘤生物标志物的临床研究现状和建议。
Neurology. 2021 Aug 17;97(7 Suppl 1):S42-S49. doi: 10.1212/WNL.0000000000012426. Epub 2021 Jul 6.
10
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.当前用于神经纤维瘤病临床试验中评估生活质量领域的患者报告结局测量的推荐意见。
Neurology. 2021 Aug 17;97(7 Suppl 1):S50-S63. doi: 10.1212/WNL.0000000000012421. Epub 2021 Jul 6.